Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
amgen
7
×
clinical trials
life sciences
national blog main
boston blog main
biotech
boston top stories
national top stories
new york blog main
new york top stories
inclisiran
new york
regeneron pharmaceuticals
alnylam pharmaceuticals
fda
pcsk9 inhibitors
san francisco blog main
san francisco top stories
sanofi
alirocumab
calcitonin gene-related peptide
cholesterol
chronic migraine
deals
drugs
eli lilly
episodic migraine
evolocumab
indiana blog main
indiana top stories
novartis
pcsk9
praluent
repatha
rna interference
teva pharmaceutical
the medicines co.
alder biopharmaceuticals
boulder/denver blog main
boulder/denver top stories
What
drug
7
×
medicines
7
×
cholesterol
fda
medco
new
lowering
announced
approval
class
developed
migraine
pain
starts
twice
won
aces
acquire
agreed
alnylam
amgen
approved
based
big
billion
bringing
brings
cancer
candidates
cash
ceo
clears
closer
company
compound
data
deal
decision
despite
eli
Language
unset
Current search:
medicines
×
drug
×
amgen
×
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com
4 years ago
MedCo Preps for FDA Filing as Cholesterol Drug Clears Last Two Tests
@xconomy.com
4 years ago
As Cholesterol Drug Aces Big Test, MedCo CEO Open to Flexible Pricing
@xconomy.com
4 years ago
MedCo Touts New Data for Long-Lasting Heart Drug as Reckoning Looms
@xconomy.com
5 years ago
Eli Lilly Migraine Drug Approved, the Third in New Class of Medicines
@xconomy.com
5 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines